Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. reported a change on its Board of Directors. On June 27, 2026, Class II director Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA, resigned from the Board and from the Scientific Advisory Board, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
On July 1, 2026, the Board elected Nasim Shomali as a Class II director to serve until the 2027 annual meeting of stockholders. She previously served as a Strategy Executive at Accenture from April 2013 to April 2026, advising large companies on enterprise strategy and transformation. The company notes there is no arrangement under which she was selected, and discloses that Shomali is the niece of President, Chief Executive Officer and Executive Chairman Amir Heshmatpour.
NeOnc Technologies Holdings, Inc. is calling a virtual annual stockholder meeting on August 14, 2026 at 10:00 a.m. Pacific Daylight Time. Stockholders of record as of June 15, 2026, when 25,931,865 common shares were outstanding, are entitled to vote.
Key items include electing two Class I directors (Victoria Medvec and Steven Giannotta) to three-year terms ending in 2029, approving a Plan Amendment Proposal to the 2023 Equity Incentive Plan, ratifying CBIZ CPAs P.C. as independent auditor for 2026, and an adjournment proposal. The board is classified into three staggered classes and currently has seven members, a majority of whom are deemed independent under Nasdaq rules.
The proxy explains detailed voting mechanics, including Internet, telephone, mail and in‑meeting voting, broker non-votes, and quorum requirements. It also outlines director and executive backgrounds, their cash salaries, significant restricted stock grants under the 2023 Equity Incentive Plan, existing employment agreements, and governance policies such as a clawback policy, insider trading policy, and procedures for stockholder director nominations.
NeOnc Technologies Holdings, Inc. reported that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO100, its lead intranasal nose‑to‑brain cancer therapy. The authorization covers NEO100-01, NEO100-02, and NEO100-03 protocols from Phase 1 through Phase 2 in adults, plus a pediatric pathway for Phase 1 and Phase 1b.
NEO100 targets progressive or recurrent Grade III or IV gliomas and complements NeOnc’s existing UAE IND for its NEO212 program. In the United States, NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and the NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with top-line data expected by the end of July 2026.
NeOnc Technologies Holdings, Inc. is registering for resale up to 555,554 shares of Common Stock, consisting of 277,777 issued shares and 277,777 shares issuable upon exercise of a Warrant. The registration enables the named selling stockholder to offer and sell the Shares from time to time at fixed or prevailing market prices or by negotiated transactions. The Company is not selling shares hereunder and will not receive proceeds from resales, although the Company may receive cash proceeds if the Warrant is exercised for cash. The Warrant has a $9.00 exercise price, a five-year term and beneficial ownership exercise limits (4.99%/9.99% features). Shares outstanding were 25,933,365 as of June 12, 2026.
NeOnc Technologies Holdings, Inc. reported that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status in the United Arab Emirates for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This is the first international regulatory clearance for NEO212 following completion of Phase 1 evaluation.
The Phase 1 dose-escalation study established 610 mg as the recommended Phase 2 dose and showed early signs of clinical activity in heavily pretreated patients with recurrent glioblastoma and brain metastases. The new authorization is expected to support advancement into Phase 2 in the UAE, alongside ongoing U.S. FDA discussions on a potential registrational pathway.
Before enrolling patients in the UAE, NeOnc must obtain DOH Institutional Review Board approval and update its study documents and labeling. The clearance covers clinical research only and is not a marketing authorization. NeOnc has also applied in Abu Dhabi for several NEO100 programs, aiming to expand its brain cancer and neurological pipeline internationally.
NeOnc Technologies Holdings, Inc. is registering 555,554 shares of Common Stock for resale by a selling stockholder, consisting of 277,777 issued shares and 277,777 shares issuable upon exercise of a five-year Warrant. The Company will not receive proceeds from resales; proceeds only arise if the Warrant is exercised for cash.
The prospectus states 25,933,365 shares outstanding as of June 12, 2026 and cites a last reported Nasdaq sale price of $4.75 per share as of June 12, 2026. The resale registration covers shares issued under a private placement and the related Warrant with a $9.00 initial exercise price and beneficial ownership exercise limits (4.99%/9.99%).
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors to sell up to $5,000,000 of Series A Convertible Preferred Stock in a private placement. Up to 6,000 preferred shares will be issued at $833.34 per share, each with a stated value of $1,000.
The preferred stock ranks senior to common stock in a liquidation and carries no general voting rights. The company may redeem all Series A shares at stated value within four months, with two one‑month extension options that each add $50 per share. If the company elects not to redeem, an additional $166.67 per share is added and the shares become convertible into common stock at 80% of the lowest closing price over the prior five trading days, subject to a $1.00 floor, a 19.99% conversion cap without stockholder approval, and a beneficial ownership limit of 4.99% or 9.99% per holder.
NeOnc Technologies Holdings, Inc. is soliciting proxies for its virtual Annual Meeting of Stockholders to be held on August 14, 2026 at 10:00 a.m. Pacific Daylight Time. The Board fixed June 15, 2026 as the record date for voting.
The meeting agenda includes the election of two Class I directors, approval of a Plan Amendment, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm, and an adjournment proposal. Voting instructions, internet and telephone voting procedures, and proxy access rules are described herein.
NeOnc Technologies Holdings used this report to share first quarter 2026 results and progress in its brain cancer programs. For the quarter ended March 31, 2026, GAAP net loss was $8.8 million, and non-GAAP normalized cash operating expenses were $6.1 million.
Clinically, the company completed Phase 1 dose escalation for NEO212 and set 610 mg as the recommended Phase 2 dose, while its Phase 2a NEO100 study moves toward an interim readout supported by previously reported 24% radiographic remission and 44% six‑month progression-free survival. NeOnc also arranged a $10 million PIPE financing led by Cinctive Capital and noted an open‑market insider share purchase of more than $500,000.